Expert Review of Anticancer Therapy最新文献

Prostate cancer prediction through a hybrid deep learning method applied to histopathological image. 应用于组织病理图像的混合深度学习方法预测前列腺癌。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-28 DOI: 10.1080/14737140.2025.2512040

P Poonkuzhali, R Krishnamoorthy, Divya Nimma, Janjhyam Venkata Naga Ramesh

{"title":"Prostate cancer prediction through a hybrid deep learning method applied to histopathological image.","authors":"P Poonkuzhali, R Krishnamoorthy, Divya Nimma, Janjhyam Venkata Naga Ramesh","doi":"10.1080/14737140.2025.2512040","DOIUrl":"10.1080/14737140.2025.2512040","url":null,"abstract":"Background: Prostate Cancer (PCa) is a severe disease that affects males globally. The Gleason grading system is a widely recognized method for diagnosing the aggressiveness of PCa using histopathological images. This system evaluates prostate tissue to determine the severity of the disease and guide treatment decisions. However, manual analysis of histopathological images requires highly skilled professionals and is time-consuming.Methods: To address these challenges, deep learning (DL) is utilized, as it has shown promising results in medical image analysis. Although numerous DL networks have been developed for Gleason grading, many existing methods have limitations such as suboptimal accuracy and high computational complexity. The proposed network integrates MobileNet, an Attention Mechanism (AM), and a capsule network. MobileNet efficiently extracts features from images while addressing computational complexity. The AM focuses on selecting the most relevant features, enhancing the accuracy of Gleason grading. Finally, the capsule network classifies the Gleason grades from histopathological images.Results: The validation of the proposed network used two datasets, PANDA and Gleason-2019. Ablation studies were conducted and evaluated in the proposed architecture. The results highlight the effectiveness of the proposed network.Conclusions: The proposed network outperformed existing approaches, achieving an accuracy of 98.08% on the PANDA dataset and 97.07% on the Gleason-2019 dataset.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":2.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk-reducing mastectomy in healthy women with BRCA mutation: a narrative review. BRCA突变健康女性乳房切除术降低风险：一项叙述性回顾

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-28 DOI: 10.1080/14737140.2025.2513451

Calogero Cipolla, Giuseppa Scandurra, Daniela Sambataro, Chiara Mesi, Martina Greco, Eleonora D'Agati, Vittorio Gebbia, Maria Rosaria Valerio

{"title":"Risk-reducing mastectomy in healthy women with BRCA mutation: a narrative review.","authors":"Calogero Cipolla, Giuseppa Scandurra, Daniela Sambataro, Chiara Mesi, Martina Greco, Eleonora D'Agati, Vittorio Gebbia, Maria Rosaria Valerio","doi":"10.1080/14737140.2025.2513451","DOIUrl":"https://doi.org/10.1080/14737140.2025.2513451","url":null,"abstract":"Introduction: Breast cancer (BC) prevention in BRCA1/2 mutation carriers remains a significant clinical challenge. Risk-reducing mastectomy (RRM) is the most effective preventive option, lowering BC incidence by over 90%. Despite its survival benefit, the decision to undergo RRM is complex and shaped by psychological, social, and healthcare access factors.Areas covered: This narrative review synthesizes evidence on the oncologic efficacy, safety, and outcomes of RRM in BRCA mutation carriers. Literature was identified through PubMed, Scopus, and Web of Science up to March 2025. Large cohort studies and systematic reviews confirm the effectiveness of RRM. Nipple-sparing mastectomy offers comparable oncologic safety with improved cosmetic and psychological outcomes. Histopathologic analyses frequently reveal occult malignancies, supporting the role of early surgery. However, surgical complications, sensory loss, and sexual health impacts remain important considerations.Expert opinion: RRM is cost-effective, especially when performed at younger ages, but disparities in access to genetic testing and surgery persist. Special populations, such as ovarian cancer survivors and those diagnosed before genetic testing, require individualized care. Advances in risk stratification, surgical techniques, and psychosocial support will enhance outcomes. A multidisciplinary, patient-centered approach is essential for informed decision-making.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Computational modeling of breast tissue mechanics and machine learning in cancer diagnostics: enhancing precision in risk prediction and therapeutic strategies. 乳腺组织力学和机器学习在癌症诊断中的计算建模：提高风险预测和治疗策略的准确性。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-28 DOI: 10.1080/14737140.2025.2508850

Layal Ashi, Sebastien Taurin

{"title":"Computational modeling of breast tissue mechanics and machine learning in cancer diagnostics: enhancing precision in risk prediction and therapeutic strategies.","authors":"Layal Ashi, Sebastien Taurin","doi":"10.1080/14737140.2025.2508850","DOIUrl":"10.1080/14737140.2025.2508850","url":null,"abstract":"Introduction: Breast cancer remains a significant global health issue. Despite advances in detection and treatment, its complexity is driven by genetic, environmental, and structural factors. Computational methods like Finite Element Modeling (FEM) have transformed our understanding of breast cancer risk and progression.Areas covered: Advanced computational approaches in breast cancer research are the focus, with an emphasis on FEM's role in simulating breast tissue mechanics and enhancing precision in therapies such as radiofrequency ablation (RFA). Machine learning (ML), particularly Convolutional Neural Networks (CNNs), has revolutionized imaging modalities like mammograms and MRIs, improving diagnostic accuracy and early detection. AI applications in analyzing histopathological images have advanced tumor classification and grading, offering consistency and reducing inter-observer variability. Explainability tools like Grad-CAM, SHAP, and LIME enhance the transparency of AI-driven models, facilitating their integration into clinical workflows.Expert opinion: Integrating FEM and ML represents a paradigm shift in breast cancer management. FEM offers precise modeling of tissue mechanics, while ML excels in predictive analytics and image analysis. Despite challenges such as data variability and limited standardization, synergizing these approaches promises adaptive, personalized care. These computational methods have the potential to redefine diagnostics, optimize treatment, and improve patient outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Accuracy of high b-value diffusion-weighted imaging in identifying benign and malignant breast lesions: a systematic review and meta-analysis. 高b值弥散加权成像识别乳腺良恶性病变的准确性：一项系统回顾和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-27 DOI: 10.1080/14737140.2025.2510532

Jupeng Zhang, Qi Wu, Xiqi Zhu, Baosheng Li

{"title":"Accuracy of high b-value diffusion-weighted imaging in identifying benign and malignant breast lesions: a systematic review and meta-analysis.","authors":"Jupeng Zhang, Qi Wu, Xiqi Zhu, Baosheng Li","doi":"10.1080/14737140.2025.2510532","DOIUrl":"10.1080/14737140.2025.2510532","url":null,"abstract":"Objective: To evaluate the diagnostic accuracy of high b-value diffusion-weighted imaging (DWI) in differentiating malignant from benign breast lesions.Methods: A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, Scopus, and Web of Science for English-language studies on high b-value DWI in breast lesions, from inception to June 2024. Study quality was assessed, and data were extracted. Heterogeneity analysis, forest plots, Deek's funnel plots, and summary receiver operating characteristic (SROC) curves were generated using Stata 16.0 and Meta-Disc 1.4 software. Meta-regression identified sources of heterogeneity.Results: The meta-analysis included 12 studies with 1,747 patients and 1,861 breast lesions (1,000 malignant, 861 benign). Pooled diagnostic metrics were: sensitivity, 0.91 (95% CI: 0.87-0.94); specificity, 0.93 (95% CI: 0.87-0.96); positive likelihood ratio, 12.21 (95% CI: 6.91-21.57); negative likelihood ratio, 0.09 (95% CI: 0.06-0.14); diagnostic odds ratio, 130.75 (95% CI: 56.95-300.21); and AUC, 0.97 (95% CI: 0.95-0.98).Conclusion: High b-value DWI has high diagnostic accuracy in differentiating between benign and malignant breast lesions, demonstrating potential as a reliable imaging marker.Registration: PROSPERO (CRD42024568777).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The use of ctDNA for muscle-invasive bladder cancer before and after radical cystectomy. ctDNA在肌肉浸润性膀胱癌根治性膀胱切除术前后的应用

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-26 DOI: 10.1080/14737140.2025.2512036

Ioannis Manolitsis, Konstantinos Kapriniotis, Stamatios Katsimperis, Panagiotis Angelopoulos, Panagiotis Triantafyllou, Theodoros Karagiotis, Patrick Juliebo-Jones, Iraklis Mitsogiannis, Bhaskar Somani, Andreas Skolarikos, Lazaros Tzelves

{"title":"The use of ctDNA for muscle-invasive bladder cancer before and after radical cystectomy.","authors":"Ioannis Manolitsis, Konstantinos Kapriniotis, Stamatios Katsimperis, Panagiotis Angelopoulos, Panagiotis Triantafyllou, Theodoros Karagiotis, Patrick Juliebo-Jones, Iraklis Mitsogiannis, Bhaskar Somani, Andreas Skolarikos, Lazaros Tzelves","doi":"10.1080/14737140.2025.2512036","DOIUrl":"https://doi.org/10.1080/14737140.2025.2512036","url":null,"abstract":"Introduction: Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy with high recurrence rates despite standard treatment with radical cystectomy with neoadjuvant chemotherapy. Conventional imaging and histopathology have limited ability to detect minimal residual disease (MRD) or predict treatment response. Circulating tumor DNA (ctDNA), has emerged as a promising noninvasive biomarker for dynamic tumor monitoring and risk stratification.Areas covered: This review explores the current and emerging applications of ctDNA in MIBC, including its use in neoadjuvant and adjuvant settings, MRD detection, surveillance, and treatment guidance. Key clinical trials, such as IMvigor010/011, ABACUS, NABUCCO, TOMBOLA, MODERN, and VOLGA are discussed, highlighting the prognostic and predictive value of ctDNA across disease stages. Technical and biological limitations are examined, along with challenges related to standardization, cost, and clinical integration.Expert opinion: ctDNA is poised to transform the perioperative management of MIBC by enabling precision-guided treatment decisions. ctDNA assays offer high sensitivity for MRD detection and early relapse prediction. While not yet part of routine clinical practice, ongoing studies will determine whether ctDNA-guided interventions improve patient outcomes. With continued advancements in assay sensitivity, bioinformatics, and integration with radiomic and genomic data, ctDNA is expected to become a cornerstone in the treatment of urothelial carcinoma.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring different techniques for endoscopic submucosal dissection of gastrointestinal lesions: a review of the literature. 探讨内镜下粘膜下解剖胃肠道病变的不同技术：文献综述。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-23 DOI: 10.1080/14737140.2025.2504472

Giulio Calabrese, Marcello Maida, Darshan Parekh, Yohei Minato, Alessandro Vitello, Alberto Murino, Rui Morais, Emanuele Sinagra, Daryl Ramai, Ken Ohata, Sandro Sferrazza

{"title":"Exploring different techniques for endoscopic submucosal dissection of gastrointestinal lesions: a review of the literature.","authors":"Giulio Calabrese, Marcello Maida, Darshan Parekh, Yohei Minato, Alessandro Vitello, Alberto Murino, Rui Morais, Emanuele Sinagra, Daryl Ramai, Ken Ohata, Sandro Sferrazza","doi":"10.1080/14737140.2025.2504472","DOIUrl":"10.1080/14737140.2025.2504472","url":null,"abstract":"Introduction: Endoscopic submucosal dissection (ESD) has revolutionized the management of early gastrointestinal (GI) neoplasms by enabling en bloc resection with high R0 rates. Several modifications of conventional ESD (C-ESD) have been introduced, including pocket-creation (PCM-ESD), tunnel (T-ESD), traction-assisted (TA-ESD), and saline immersion therapeutic endoscopy (SITE-ESD) methods.Areas covered: A comprehensive literature search was conducted across main databases through February 2025 using keywords related to ESD, with studies selected based on their relevance. While no single technique has demonstrated superior efficacy and safety across different GI regions, a tailored and integrative approach to different techniques could enhance effectiveness. PCM-ESD and T-ESD are particularly advantageous circumferential lesions in the esophagus and rectum, whereas TA-ESD significantly reduces procedure time, particularly in colonic lesions. Moreover, PCM-ESD has demonstrated higher effectiveness for colorectal lesions compared to C-ESD. SITE-ESD has shown benefits in colorectal resections by improving trimming, submucosal space visualization and coagulation control.Advanced traction systems and resection tools has optimized ESD performance. However, selecting the most appropriate approach requires careful consideration of lesion characteristics (particularly fibrosis and location).Expert opinion: While conventional ESD remains the foundation, TA and SITE are expected to become the preferred approach in select GI regions during the following years.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":2.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer. 新发小体积转移性激素敏感前列腺癌的当前诊断和治疗选择。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-21 DOI: 10.1080/14737140.2025.2509760

Gianluca Ingrosso, Andrea Lancia, Lilia Bardoscia, Carlotta Becherini, Marta Bottero, Niccolò Bertini, Tommaso Cai, Saverio Caini, Claudia Caserta, Chiara Doccioli, Eleonora Festa, Giulio Francolini, Irene Giacomelli, Federico Paolieri, Daniele Scartoni, Antonio Rosario Pisani, Rita Bellavita, Lorenzo Livi, Cynthia Aristei, Beatrice Detti

{"title":"Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer.","authors":"Gianluca Ingrosso, Andrea Lancia, Lilia Bardoscia, Carlotta Becherini, Marta Bottero, Niccolò Bertini, Tommaso Cai, Saverio Caini, Claudia Caserta, Chiara Doccioli, Eleonora Festa, Giulio Francolini, Irene Giacomelli, Federico Paolieri, Daniele Scartoni, Antonio Rosario Pisani, Rita Bellavita, Lorenzo Livi, Cynthia Aristei, Beatrice Detti","doi":"10.1080/14737140.2025.2509760","DOIUrl":"10.1080/14737140.2025.2509760","url":null,"abstract":"Introduction: de novo low-volume metastatic hormone-sensitive prostate cancer (mHSPC) patients are characterized by a limited number of metastases at diagnosis. Intensifying the current diagnostic and therapeutic approach including multimodality therapy seems to be key in the clinical management of such patients.Areas covered: We comprehensively review the current staging and treatment options for de novo low-volume mHSPC.Expert opinion: PSMA-PET should be used in staging high-risk prostate cancer to detect metastatic disease and better stratify patients for individualized treatment. In the era of Androgen Receptor Pathway Inhibitors (ARPIs), Androgen Deprivation Therapy (ADT) alone should be considered an undertreatment for the majority of the patients. Based on current data in the literature, the most effective therapeutic strategy seems to be the combination of intensified systemic treatment (including ADT + ARPI) and radiotherapy for the primary tumor. The role of cytoreductive radical prostatectomy is currently being investigated as well as metastasis-directed therapy to metastatic sites.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.9,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The new insights of surgery for locally advanced head and neck cancer. 局部晚期头颈癌手术治疗的新见解。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-15 DOI: 10.1080/14737140.2025.2507687

Yat-Fung Chow, Peter Mu-Hsin Chang

引用次数: 0

Diagnostic accuracy of lateral lymph node metastasis for locally advanced rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis. 局部晚期直肠癌新辅助治疗后外侧淋巴结转移的诊断准确性：一项系统回顾和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-15 DOI: 10.1080/14737140.2025.2506646

Kosuke Ozaki, Kazushige Kawai, Shimpei Ogawa, Yukihide Kanemitsu, Yoichi Ajioka

{"title":"Diagnostic accuracy of lateral lymph node metastasis for locally advanced rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis.","authors":"Kosuke Ozaki, Kazushige Kawai, Shimpei Ogawa, Yukihide Kanemitsu, Yoichi Ajioka","doi":"10.1080/14737140.2025.2506646","DOIUrl":"10.1080/14737140.2025.2506646","url":null,"abstract":"Background: The optimal criteria for lateral lymph node dissection (LLND) in rectal cancer following neoadjuvant therapy remain undefined. This systematic review and meta-analysis evaluated the diagnostic accuracy of lateral lymph node metastasis (LLNM) to refine criteria for selective LLND.Research design and methods: A systematic search of PubMed, Embase, and the Cochrane Library (10 August 2024) identified studies assessing magnetic resonance imaging (MRI)-based LLNM detection in patients with rectal cancer who underwent neoadjuvant therapy and radical surgery. Studies reporting MRI-based LLNM assessments with pathological confirmation were included. Non-English studies, reviews, case reports, and those lacking lymph node size data were excluded. The risk of bias was assessed using QUADAS-2. Pooled sensitivity, specificity, and diagnostic odds ratios were estimated using hierarchical summary receiver operating characteristic curve (HSROC) analysis.Results: Eleven studies met the inclusion criteria. All used MRI-based size assessments. The pooled sensitivity and specificity were 0.776 (95% CI: 0.639-0.872) and 0.694 (95% CI: 0.541-0.813), respectively, with an HSROC area under the curve (AUC) of 0.801.Conclusions: MRI is the most widely used modality for diagnosing LLNM in rectal cancer patients who have undergone neoadjuvant therapy, with size criteria being the most commonly applied.Registration: PROSPERO (CRD42024578499).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.9,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding myokine Irisin's function in oral cancer: therapeutic and prognostic consequences. 了解肌因子鸢尾素在口腔癌中的作用：治疗和预后后果。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-09 DOI: 10.1080/14737140.2025.2504471

Kaviyarasi Renu

引用次数: 0